The U.S. Federal Trade Commission (FTC) and seven states ask a federal judge to hold Martin Shkreli in contempt, alleging he “flagrantly and repeatedly” violated a lifetime ban tied to his release from prison. The request is filed in the U.S. District Court for the Southern District of New York.
According to the regulators, conditions of Shkreli’s 2022 release bar him from participating in the pharmaceutical industry, including owning stakes or making decisions connected to such businesses. Multiple outlets report the filings allege he traded stocks in at least dozens of pharmaceutical companies and provided public commentary—described in coverage as investment-related—about biopharma companies since his release.
Outlets largely focus on the same core allegations and the contempt request, with some highlighting the market angle (stock trading and social media commentary) and others emphasizing the original basis for the ban. The filings seek court enforcement of the restrictions, including possible penalties for noncompliance, but the judge has not yet ruled.
